Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Breast 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Other 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Sarcoma 1Lymphoma 1Hematologic Neoplasms 1Cardiotoxicity 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lisinopril × Breast × Clear all
NCT04190433 2023-05-24

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Mayo Clinic

Phase 2 Withdrawn
BreastLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms

NCT01009918 2021-03-30

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

University of South Florida

Phase 2 Completed
468 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡